Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bristol-Myers Squibb

50.57
+0.96001.94%
Post-market: 50.680.1100+0.22%19:58 EDT
Volume:14.17M
Turnover:712.67M
Market Cap:102.91B
PE:18.94
High:50.65
Open:50.11
Low:49.68
Close:49.61
Loading ...

Bristol Myers Squibb's Schizophrenia Treatment Falls Flat

Dow Jones
·
23 Apr

BRIEF-Bristol Myers Squibb Announces Topline Results From Phase 3 Arise Trial Evaluating Cobenfy As An Adjunctive Treatment To Atypical Antipsychotics In Adults With Schizophrenia

Reuters
·
23 Apr

Bristol Myers Squibb Co. Stock Rises Tuesday, Still Underperforms Market

Dow Jones
·
23 Apr

BUZZ-Bristol Myers drops as schizophrenia drug fails in late-stage trial as add-on treatment

Reuters
·
23 Apr

Bristol Myers' Cobenfy fails in key study as add-on treatment for schizophrenia

Reuters
·
23 Apr

Bristol-Myers Squibb Shares Down 7.6% After the Bell Following Announcement Its Cobenfy Schizophrenia Treatment Did Not Reach Statistical Significance in Phase 3 Trial

THOMSON REUTERS
·
23 Apr

Bristol Myers' Cobenfy fails to meet main goal as add-on treatment for schizophrenia

Reuters
·
23 Apr

Bristol-Myers Squibb Co - Cobenfy Safety and Tolerability Consistent With Previous Trials

THOMSON REUTERS
·
23 Apr

Bristol-Myers Squibb Co - Cobenfy Did Not Reach Statistical Significance in Phase 3 Trial

THOMSON REUTERS
·
23 Apr

Bristol Myers Squibb Announces Topline Results From Phase 3 Arise Trial Evaluating Cobenfy (Xanomeline and Trospium Chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults With Schizophrenia

THOMSON REUTERS
·
23 Apr

Top Calls on Wall Street: Apple, Nvidia, Tesla, Amazon, Meta, Disney, McDonald’s & More

Tiger Newspress
·
22 Apr

Market Chatter: Trump Administration Mulls Cutting US Drug Prices to International Levels

MT Newswires Live
·
22 Apr

Trump Mulls Cutting US Drug Prices to International Levels, Reuters Reports

MT Newswires Live
·
22 Apr

NeoGenomics (NEO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks
·
22 Apr

FOCUS-Trump looking at cutting US drug prices to international levels, sources say

Reuters
·
22 Apr

Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term

Zacks
·
22 Apr

Bristol-Myers Squibb Coverage Assumed by Cantor Fitzgerald at Neutral

Dow Jones
·
22 Apr

Bristol-Myers Squibb (BMY) Has a New Rating from Cantor Fitzgerald

TIPRANKS
·
22 Apr

Piper Sandler Initiates Bristol-Myers Squibb at Overweight With $65 Price Target

MT Newswires Live
·
22 Apr

Cytokinetics reiterated as top pick at H.C. Wainwright, Camzyos updates positive

TIPRANKS
·
21 Apr